Cargando…

Tacrolimus interacts with voriconazole to reduce the severity of fungal keratitis by suppressing IFN-related inflammatory responses and concomitant FK506 and voriconazole treatment suppresses fungal keratitis

PURPOSE: To investigate the expression and roles of type I and II interferons (IFNs) in fungal keratitis, as well as the therapeutic effects of tacrolimus (FK506) and voriconazole on this condition. METHODS: The mRNA and protein expression levels of type I (IFN-α/β) and II (IFN-γ) IFNs, as well as o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Jing, Peng, Lulu, Wang, Bowen, Zhang, Henan, Li, Saiqun, Yang, Ruhui, Deng, Yuqing, Huang, Haixiang, Yuan, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Vision 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836723/
https://www.ncbi.nlm.nih.gov/pubmed/29527115
_version_ 1783304001589084160
author Zhong, Jing
Peng, Lulu
Wang, Bowen
Zhang, Henan
Li, Saiqun
Yang, Ruhui
Deng, Yuqing
Huang, Haixiang
Yuan, Jin
author_facet Zhong, Jing
Peng, Lulu
Wang, Bowen
Zhang, Henan
Li, Saiqun
Yang, Ruhui
Deng, Yuqing
Huang, Haixiang
Yuan, Jin
author_sort Zhong, Jing
collection PubMed
description PURPOSE: To investigate the expression and roles of type I and II interferons (IFNs) in fungal keratitis, as well as the therapeutic effects of tacrolimus (FK506) and voriconazole on this condition. METHODS: The mRNA and protein expression levels of type I (IFN-α/β) and II (IFN-γ) IFNs, as well as of related downstream inflammatory cytokines (interleukin (IL)-1α, IL-6, IL-12, and IL-17), were detected in macrophages, neutrophils, lymphocytes, and corneal epithelial cells (A6(1) cells) stimulated with zymosan (10 mg/ml) for 8 or 24 h. A fungal keratitis mouse model was generated through intrastromal injection of Aspergillus fumigatus, and the mice were then divided into four groups: group I, the PBS group; group II, the voriconazole group; group III, the FK506 group; and group IV, the voriconazole plus 0.05% FK506 group. Corneal damage was evaluated with clinical scoring and histological examination. In addition, the mRNA and protein expression levels of type I (IFN-α/β) and type II (IFN-γ) IFNs, as well as related inflammatory cytokines, were determined at different time points using quantitative real-time PCR (qRT-PCR) and western blotting. RESULTS: After zymosan stimulation of mouse neutrophils, lymphocytes, macrophages, and A6(1) cells, the IFN mRNA and protein expression levels were markedly increased until 24 h, peaking at 8 h (p<0.001). The mRNA and protein expression levels of inflammatory cytokines (IL-1α, IL-6, IL-12, and IL-17) were also upregulated after zymosan stimulation. Moreover, type I (IFN-α/β) and type II (IFN-γ) IFN expression levels were increased and positively correlated with the progression of fungal keratitis in vivo. FK506 administered with voriconazole reduced the pathological infiltration of inflammatory cells into the cornea and downregulated the expression levels of IFNs and related inflammatory cytokines. CONCLUSIONS: In conclusion, this study demonstrated that type I and II IFN levels were markedly increased in fungal keratitis and that FK506 combined with voriconazole decreased the severity of fungal keratitis by suppressing type I and II IFNs and their related inflammatory responses.
format Online
Article
Text
id pubmed-5836723
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Molecular Vision
record_format MEDLINE/PubMed
spelling pubmed-58367232018-03-09 Tacrolimus interacts with voriconazole to reduce the severity of fungal keratitis by suppressing IFN-related inflammatory responses and concomitant FK506 and voriconazole treatment suppresses fungal keratitis Zhong, Jing Peng, Lulu Wang, Bowen Zhang, Henan Li, Saiqun Yang, Ruhui Deng, Yuqing Huang, Haixiang Yuan, Jin Mol Vis Research Article PURPOSE: To investigate the expression and roles of type I and II interferons (IFNs) in fungal keratitis, as well as the therapeutic effects of tacrolimus (FK506) and voriconazole on this condition. METHODS: The mRNA and protein expression levels of type I (IFN-α/β) and II (IFN-γ) IFNs, as well as of related downstream inflammatory cytokines (interleukin (IL)-1α, IL-6, IL-12, and IL-17), were detected in macrophages, neutrophils, lymphocytes, and corneal epithelial cells (A6(1) cells) stimulated with zymosan (10 mg/ml) for 8 or 24 h. A fungal keratitis mouse model was generated through intrastromal injection of Aspergillus fumigatus, and the mice were then divided into four groups: group I, the PBS group; group II, the voriconazole group; group III, the FK506 group; and group IV, the voriconazole plus 0.05% FK506 group. Corneal damage was evaluated with clinical scoring and histological examination. In addition, the mRNA and protein expression levels of type I (IFN-α/β) and type II (IFN-γ) IFNs, as well as related inflammatory cytokines, were determined at different time points using quantitative real-time PCR (qRT-PCR) and western blotting. RESULTS: After zymosan stimulation of mouse neutrophils, lymphocytes, macrophages, and A6(1) cells, the IFN mRNA and protein expression levels were markedly increased until 24 h, peaking at 8 h (p<0.001). The mRNA and protein expression levels of inflammatory cytokines (IL-1α, IL-6, IL-12, and IL-17) were also upregulated after zymosan stimulation. Moreover, type I (IFN-α/β) and type II (IFN-γ) IFN expression levels were increased and positively correlated with the progression of fungal keratitis in vivo. FK506 administered with voriconazole reduced the pathological infiltration of inflammatory cells into the cornea and downregulated the expression levels of IFNs and related inflammatory cytokines. CONCLUSIONS: In conclusion, this study demonstrated that type I and II IFN levels were markedly increased in fungal keratitis and that FK506 combined with voriconazole decreased the severity of fungal keratitis by suppressing type I and II IFNs and their related inflammatory responses. Molecular Vision 2018-03-04 /pmc/articles/PMC5836723/ /pubmed/29527115 Text en Copyright © 2018 Molecular Vision. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited, used for non-commercial purposes, and is not altered or transformed.
spellingShingle Research Article
Zhong, Jing
Peng, Lulu
Wang, Bowen
Zhang, Henan
Li, Saiqun
Yang, Ruhui
Deng, Yuqing
Huang, Haixiang
Yuan, Jin
Tacrolimus interacts with voriconazole to reduce the severity of fungal keratitis by suppressing IFN-related inflammatory responses and concomitant FK506 and voriconazole treatment suppresses fungal keratitis
title Tacrolimus interacts with voriconazole to reduce the severity of fungal keratitis by suppressing IFN-related inflammatory responses and concomitant FK506 and voriconazole treatment suppresses fungal keratitis
title_full Tacrolimus interacts with voriconazole to reduce the severity of fungal keratitis by suppressing IFN-related inflammatory responses and concomitant FK506 and voriconazole treatment suppresses fungal keratitis
title_fullStr Tacrolimus interacts with voriconazole to reduce the severity of fungal keratitis by suppressing IFN-related inflammatory responses and concomitant FK506 and voriconazole treatment suppresses fungal keratitis
title_full_unstemmed Tacrolimus interacts with voriconazole to reduce the severity of fungal keratitis by suppressing IFN-related inflammatory responses and concomitant FK506 and voriconazole treatment suppresses fungal keratitis
title_short Tacrolimus interacts with voriconazole to reduce the severity of fungal keratitis by suppressing IFN-related inflammatory responses and concomitant FK506 and voriconazole treatment suppresses fungal keratitis
title_sort tacrolimus interacts with voriconazole to reduce the severity of fungal keratitis by suppressing ifn-related inflammatory responses and concomitant fk506 and voriconazole treatment suppresses fungal keratitis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836723/
https://www.ncbi.nlm.nih.gov/pubmed/29527115
work_keys_str_mv AT zhongjing tacrolimusinteractswithvoriconazoletoreducetheseverityoffungalkeratitisbysuppressingifnrelatedinflammatoryresponsesandconcomitantfk506andvoriconazoletreatmentsuppressesfungalkeratitis
AT penglulu tacrolimusinteractswithvoriconazoletoreducetheseverityoffungalkeratitisbysuppressingifnrelatedinflammatoryresponsesandconcomitantfk506andvoriconazoletreatmentsuppressesfungalkeratitis
AT wangbowen tacrolimusinteractswithvoriconazoletoreducetheseverityoffungalkeratitisbysuppressingifnrelatedinflammatoryresponsesandconcomitantfk506andvoriconazoletreatmentsuppressesfungalkeratitis
AT zhanghenan tacrolimusinteractswithvoriconazoletoreducetheseverityoffungalkeratitisbysuppressingifnrelatedinflammatoryresponsesandconcomitantfk506andvoriconazoletreatmentsuppressesfungalkeratitis
AT lisaiqun tacrolimusinteractswithvoriconazoletoreducetheseverityoffungalkeratitisbysuppressingifnrelatedinflammatoryresponsesandconcomitantfk506andvoriconazoletreatmentsuppressesfungalkeratitis
AT yangruhui tacrolimusinteractswithvoriconazoletoreducetheseverityoffungalkeratitisbysuppressingifnrelatedinflammatoryresponsesandconcomitantfk506andvoriconazoletreatmentsuppressesfungalkeratitis
AT dengyuqing tacrolimusinteractswithvoriconazoletoreducetheseverityoffungalkeratitisbysuppressingifnrelatedinflammatoryresponsesandconcomitantfk506andvoriconazoletreatmentsuppressesfungalkeratitis
AT huanghaixiang tacrolimusinteractswithvoriconazoletoreducetheseverityoffungalkeratitisbysuppressingifnrelatedinflammatoryresponsesandconcomitantfk506andvoriconazoletreatmentsuppressesfungalkeratitis
AT yuanjin tacrolimusinteractswithvoriconazoletoreducetheseverityoffungalkeratitisbysuppressingifnrelatedinflammatoryresponsesandconcomitantfk506andvoriconazoletreatmentsuppressesfungalkeratitis